Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2014

View Archived Issues

Phase III trial of orteronel plus prednisone in patients with mCRPC does not meet primary endpoint

AstraZeneca reflects on achievements of fourth quarter 2013

La Jolla Pharmaceutical licenses hepcidin technology from INSERM

IMPACT Therapeutics patents new sonic hedgehog protein inhibitors for cancer

Researchers in Pamplona disclose novel agents for coagulation disorders

Researchers in the U.S. disclose novel EP4 receptor agonists

Mast Therapeutics to acquire Aires Pharmaceuticals in all-stock transaction

The University of Notre Dame du Lac develops novel agents for tuberculosis

Takara Bio and Mie University prepare phase I study of TBI-1201 gene therapy

Phase I trial assesses malaria vaccine candidate based on iBio's proprietary technology

Scientists at Confluence Life Sciences disclose new TAK1 inhibitors for cancer

New HIV integrase inhibitors patented by Merck & Co.

First patient receives PDS Biotechnology's PDS-0101 in phase I trial

Kareus Therapeutics cleared to begin phase I trial of KU-5039 in diabetes

Alba Therapeutics phase IIb trial has positive outcome in celiac disease

KaloBios begins phase II expansion portion of KB-004 study

Debiopharm to acquire Affinium's antibiotic clinical assets and platform

Sprout Pharmaceuticals receives clear guidance from FDA on flibanserin

Omeros reports additional phase I data for OMS-824

Merck & Co. and Samsung Bioepis to develop insulin glargine candidate

Nestle acquires L'Oreal's stake in Galderma and launches Nestle Skin Health

Novelos Therapeutics changes name

Jazz Pharmaceuticals launches Versacloz oral suspension in U.S.

Cempra's macrolide product shows no QT effects in thorough QT study

Ario Pharma initiates phase IIa trial of TRPV1 inhibitor for cough associated with COPD

CPI-0610 demonstrates efficacy in leukemia and lymphoma models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...